For example, immunotherapy targeting the immunosuppressive checkpoint programmed cell death protein 1 (PD-1) has achieved promising results in several cancers, but anti-PD-1 antibodies have limited therapeutic efficacy in GBM patients [45, 46]. The gene discussed is PDCD1; the disease is cancer.